iTeos Therapeutics

61 articles with iTeos Therapeutics

• iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

  3/15/2023

  iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022.

• iTeos to Present at SVB Securities Global Biopharma Conference

  2/7/2023

  iTeos Therapeutics, Inc. today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference being held virtually on Tuesday, February 14, 2023 at 10:00 a.m. EST.

• iTeos Provides Business Updates and Clinical Development Plans for 2023

  1/9/2023

  iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.

• iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  iTeos Therapeutics, Inc. announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST.

• iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference

  11/22/2022

  iTeos Therapeutics, Inc. today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Piper Sandler 34th Annual Healthcare Conference in New York City on Tuesday, November 29, 2022.

• iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/10/2022

  iTeos Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022 and provided corporate highlights.

• iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/10/2022

  iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, reported financial results for the second quarter ended June 30, 2022 and provided corporate highlights.

• iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference

  8/2/2022

  iTeos Therapeutics, Inc. announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs Wide Open – Opportunities and Challenges in Immuno-Oncology” on Tuesday, August 9, 2022 at 8:00 a.m.

• 

  iTeos and GSK Mull Future of Anti-TIGIT Candidate After Genentech Flop

  5/13/2022

  Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.

• iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  iTeos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided recent corporate highlights.

• iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  3/23/2022

  iTeos Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent corporate highlights.

• iTeos to Present at the Cowen 42nd Annual Health Care Conference

  3/1/2022

  iTeos Therapeutics, Inc. today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. ET.

• iTeos to Participate in Upcoming Investor Conferences in February 2022

  2/10/2022

  iTeos Therapeutics, Inc. announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences in February.

• iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

  1/10/2022

  iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, provided a clinical development plan for its anti-TIGIT monoclonal antibody, EOS-448, and its A2A receptor antagonist, inupadenant.

• iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/3/2022

  iTeos Therapeutics, Inc. announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Conference being held virtually on Tuesday, January 11, 2022 at 11:15 a.m. ET.

• iTeos Therapeutics Set to Join S&P SmallCap 600

  12/31/2021

  iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, January 5.

• iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021

  12/9/2021

  iTeos Therapeutics, Inc. (Nasdaq: ITOS), today announced the presentation of new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021.

• iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

  11/10/2021

  iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

• iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

  11/3/2021

  iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update.

• iTeos Therapeutics to Participate in Upcoming September 2021 Investor Conferences

  9/1/2021

  iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, announced that company management will participate in five upcoming virtual investor conferences in September: